75%Confidence
0Views
FDASource
2026-03-31Date
Summary
Harvard Drug Group's packaging defect for Midodrine tablets reveals potential vulnerabilities in blister packaging processes that could compromise drug stability. This specific packaging failure might indicate broader quality issues in their packaging operations that could affect other products in their portfolio.
Actionable: Review inventory of products from this manufacturer and distributor for similar packaging concerns, particularly for moisture-sensitive medications.
AI Confidence: 75%
Data Points
firmThe Harvard Drug Group LLC
classificationClass II
statusOngoing
distributionNationwide US.
productMidodrine Hydrochloride Tablets, USP, 5 mg, 50 Tablets (5 x 10 blister packs), Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapol
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now